ANKTIVA Plus BCG Hits Primary Endpoint in BCG-Naïve Bladder Cancer Trial
IBRX has more than doubled off its 52-week low of $1.95.
Summary
The randomized, controlled QUILT-2.005 trial met its primary endpoint: adding intravesical ANKTIVA to BCG produced a statistically significant efficacy improvement over BCG alone in BCG-naïve, high-grade NMIBC patients with carcinoma in situ, with or without papillary tumors. Safety was consistent with BCG alone and no treatment-related deaths were reported. This is the frontline setting — roughly 40 years of BCG-only standard of care — and it is a much larger patient population than the BCG-unresponsive label ANKTIVA already holds. Database lock occurred October 20, 2026, and the company says the supplemental BLA is on track for submission before year-end 2026. That filing is the next hard milestone; approval would extend ANKTIVA earlier in the disease course and broaden the addressable market. The stock is up sharply on the readout, and the binary risk now shifts to FDA acceptance and review of the sBLA.
At the time of this announcement, IBRX was trading at $8.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.